1Research progress on preclinical pharmacodynamics of personalized therapeutic tumor vaccinesHE Qing, GAO Hua, WANG Jun-zhi2401-24092Advance and challenge of biosimilar's research and developmentWANG Lan2410-24243Research progress on DNA vaccines against SARS-CoV-2JIN Xiang, YU Qing-ling, ZHANG Lu-nan, HE Yue, CHENG Xin, LIU Xiao-yan, WANG Bin2425-24334Escherichia coli expression system applied in the development of recombinant human vaccines and its potential improvementLIU Li-qin, CHEN Ting-ting, LI Shao-wei, XIA Ning-shao2434-24425Development and industrialization of TCR-T cell therapyRUI Wei, LIU Guang-na, TONG Dan, JI Liang-liang, CHEN Xiao-yuan, ZHAO Xue-qiang, LIN Xin2443-24496Emerging infectious diseases and new vaccine technologiesYANG Hui-qiang, LIU Lan-jun, GE Yong-hong2450-24587Current strategy of venture investment on innovative drugWU Xia, KE Chao-jing, SHAO Rong2459-24648The submission status and considerations for pharmaceutical researches of human papillomavirus vaccineREN Hui-mei, LI Min, LUO Jian-hui2465-24699Consideration of basic technical requirements for pharmaceutical research of insulin and its analoguesCHENG Su-yuan, SAI Wen-bo, WEI Kai-kun, LUO Jian-hui2470-247510Consideration on similarity assessment of glycosylation of biosimilar productZHANG Zhong-bing, WEI Wei, LUO Jian-hui2476-248011Determination of capsular polysaccharide contents of Streptococcus pneumoniae serotypes 6B, 10A, 17F, 19A, 19F and 20 by quantitative 1H-NMR methodXU Mei-feng, CHEN Qiong, LI Mao-guang, WANG Chun-e, YE Qiang2481-248512Safety evaluation on different doses of inactivated poliomyelitis vaccineWANG Ming, GUANG Ming, GAO Zhi-gang, LIU Fang, CHEN Hai-ping2486-249013Comparison of immunogenicity and safety of inactivated poliomyelitis vaccine and live attenuated poliomyelitis vaccine in different sequential vaccination schedulesWANG Sheng-yi, YAN Shao-hong, CHANG Shao-ying, ZHANG Zhen-guo, SHI Xuan-wen, HAN Sha-sha, CHEN Hai-ping2491-249514Establishment and validation of competitive ELISA for detecting blocking activity of monoclonal antibody against SARS-CoV-2 RBDPAN Yong-bing, ZHANG Nan, ZHAN Shan-shan, GUI Fang, WANG Jiong, SONG Gang, WU Xiao-li, YANG Xiao-ming2496-250115Establishment of a reference cell line, CCRC-hMSC-S1, for the evaluation of biological effectiveness of human mesenchymal stem cellsZHANG Ke-hua, NA Tao, HAN Xiao-yan, WU Ting-ting, ZHANG Li-xia, CHEN Ping, ZHAO Nan, YUAN Bao-zhu2502-251016Detection of methylene blue residue and its application in the preparation of anti-SARS-CoV-2 virus-inactivated plasmaGONG Qin, YU Jian-hong, QIU Jing, LUO Jing, WANG Yue, LIANG Xiao-long, HOU Yong, XIONG Wei, LI Ce-sheng2511-251417Impact of multiple freeze-thaw cycles on stability of 23-valent pneumococcal capsular polysaccharideL(U) Xue-yan, ZHANG Lei, CHEN Si, YANG Luo, ZHOU Xue-yi, ZHANG Li-ping, WEN Chong-yan, CHEN Wen-min, CHEN Yi-ming, ZHANG Rui2515-2520 